Inscrição na biblioteca: Guest
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa
Journal of Environmental Pathology, Toxicology and Oncology
Fator do impacto: 1.241 FI de cinco anos: 1.349 SJR: 0.356 SNIP: 0.613 CiteScore™: 1.61

ISSN Imprimir: 0731-8898
ISSN On-line: 2162-6537

Journal of Environmental Pathology, Toxicology and Oncology

DOI: 10.1615/JEnvironPatholToxicolOncol.2014010743
pages 69-82

On the Mechanism of Cellular Toxicity in Breast Cancer by Ionizing Radiation and Chemotherapeutic Drugs

Vidhula Ahire
LARIA, iRCM, François Jacob Institute, DRF-CEA, Caen, France; UMR6252 CIMAP, CEA - CNRS– ENSICAEN, Université de Caen Normandie, Caen, France
Kaushala Prasad Mishra
Department of Life Sciences, University of Mumbai, Mumbai, India; Nehru Gram Bharati University, Allahabad, UP, India; Foundation for Education and Research, India and BM International Research Centre, Mumbai, India
G. R. Kulkarni
School of Basic Medical Science, University of Pune, Pune- 411007, India


Breast cancer is the second leading cause of cancer mortality and the most frequent cancer found in women around the globe. The development of breast cancer is a multistep and complicated process that includes the development of ductal and lobular cells into atypical hyperplasia, carcinoma in situ, and invasive carcinoma, with an ability to metastasize. The efficacy of radiotherapy in breast cancer seems to be reduced because of a frequently observed lack of cellular sensitivity to apoptosis. Both Bcl−2 and p53 are linked to apoptosis pathways and are known to play a role in the outcome of radiotherapy. Resistance of tumor cells to therapeutic drugs and the undesirable cytotoxicity of normal cells are frequently observed in treatment outcomes in clinics. Research is, therefore, needed to develop strategies for improving the protocols of chemotherapy and radiotherapy in patients with breast cancer. This review focuses on understanding the molecular mechanisms of enhanced tumor cell killing by the combined action of certain anticancer drugs together with gamma radiation in vitro, with possible implications for practical applications in clinics.

Articles with similar content:

Druggable Targets in Pancreatic Adenocarcinoma
Forum on Immunopathological Diseases and Therapeutics, Vol.5, 2014, issue 3-4
Cristina Napoli, Stefania Nobili, Ida Landini, Gabriele Perrone, Enrico Mini, Renato Tassi
Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
Critical Reviews™ in Oncogenesis, Vol.21, 2016, issue 1-2
Mark C. Kelley
Yin Yang 1 (YY1): Regulation of Survivin and Its Role In Invasion and Metastasis
Critical Reviews™ in Oncogenesis, Vol.22, 2017, issue 1-2
Nicholas R. Galloway, Kathryn F. Ball, Nathan R. Wall, TessaRae Stiff
Possible Role of Epidermal Growth Factor Receptors in the Therapy of Pancreatic Cancer
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.28, 2011, issue 4
R. S. R. Murthy, Suresh P. Vyas, Manish K. Gupta, Sahil Aggarwal, Swati Gupta
Positron Emission Tomography Imaging of Tumor Response after Photodynamic Therapy
Journal of Environmental Pathology, Toxicology and Oncology, Vol.25, 2006, issue 1-2
Johan E. van Lier, Veronique Berard, Roger Lecomte